MarketLens

The FDA Just Killed the Biotech Fast Lane—And Moderna's Stock Is the First Casualty

8 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Is the FDA Poised to Reshape the Peptide Market

4 months ago

What are the Major Headwinds and Tailwinds Shaping the Biotech Sector in 2026

6 months ago

What Just Happened with uniQure's Earnings and FDA Update

5 months ago

What Does the 400 Gbps/lane Breakthrough Mean for Data Centers

5 months ago

How a Big Bet on Cancer Vaccines Brought Moderna Back from the Brink

Moderna's melanoma vaccine data delivered a much-needed win after years of layoffs and cash burn, potentially reviving its pipeline and investor confidence. The positive readout could strengthen its o...

MRNA

Stock News•3 weeks ago

Moderna Stock Jumps on Trial Launch for Breakthrough Ebola Vaccine

Moderna's stock rose after the company launched a trial for its Ebola vaccine candidate, which targets the species behind the deadly DRC outbreak. The move signals progress in its pipeline.

MRNA

Stock News•1 months ago

Should You Buy Moderna Stock Hand Over Fist Before Aug. 5?

Moderna faces a key FDA approval decision before Aug. 5, but the event may not drive the stock higher given market expectations.

MRNA

Stock News•1 months ago

Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout

Moderna fell 11%, while ImmunityBio and Sarepta Therapeutics each dropped 8% in a broad biotech selloff Friday, reversing part of the sector's 2026 rally.

MRNA